How have VNDA shares performed in 2024?

Vanda Pharmaceuticals' stock was trading at $4.22 at the start of the year. Since then, VNDA shares have increased by 24.2% and is now trading at $5.24. View the best growth stocks for 2024 here .

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decline of 17.0% from the March 15th total of 3,000,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 4.6% of the company's shares are sold short. View Vanda Pharmaceuticals' Short Interest .

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our VNDA earnings forecast .

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings data on Wednesday, February, 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. The biopharmaceutical company had revenue of $45.27 million for the quarter, compared to analysts' expectations of $37 million. Vanda Pharmaceuticals had a net margin of 1.30% and a trailing twelve-month return on equity of 0.46%.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and Horizon Kinetics Medical ETF (MEDX) . iShares U.S. Pharmaceuticals ETF (IHE) .

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com . Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN) , Zogenix (ZGNX) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Exelixis (EXEL) , Sangamo Therapeutics (SGMO) , Array Technologies (ARRY) , Micron Technology (MU) and Novavax (NVAX) .

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.75%) and Profit Investment Management LLC (0.38%). Insiders that own company stock include Aranthan Jones II , Joakim Wijkstrom , Kevin Patrick Moran , Melissa Young, Mihael Hristos Polymeropoulos , Phaedra Chrousos , Richard W Dugan, Stephen Ray Mitchell and Timothy Williams. View institutional ownership trends .

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free VNDA Stock Alerts

$4.93

-0.31 (-5.92%)

(As of 12:28 PM ET)

Compare

Today's Range: $4.90
▼
$5.25
50-Day Range: $3.75
▼
$5.24
52-Week Range: $3.30
▼
$7.00

Volume: 2.32 million shs
Average Volume: 2.07 million shs
Market Capitalization: $283.67 million

P/E Ratio: 98.62
Dividend Yield: N/A
Price Target: N/A

Get Vanda Pharmaceuticals alerts:

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
4.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: 0.53
Based on 20 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.06) to ($0.33) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.09 out of 5 stars

Medical Sector

294th out of 913 stocks

Pharmaceutical Preparations Industry

123rd out of 426 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vanda Pharmaceuticals.

5.0

Short Interest

Percentage of Shares Shorted
4.57% of the float of Vanda Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vanda Pharmaceuticals has recently decreased by 17.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vanda Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Vanda Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Vanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for Vanda Pharmaceuticals is -1.77.

2.5

News and Social Media Coverage

News Sentiment
Vanda Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for Vanda Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
23 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.
Percentage Held by Institutions
88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vanda Pharmaceuticals is 104.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.23.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vanda Pharmaceuticals is 104.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 170.59.
Price to Book Value per Share Ratio
Vanda Pharmaceuticals has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VNDA Stock News Headlines

April 18, 2024 | finance.yahoo.com

Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash

April 18, 2024 | bizjournals.com

D.C. biotech adopts poison pill after rejecting acquisition offer

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 18, 2024 | markets.businessinsider.com

Vanda Pharma Adopts Limited Duration Stockholder Rights Plan; Stock Up

April 17, 2024 | benzinga.com

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

April 17, 2024 | msn.com

Biggest stock movers today: ADSK, VNDA, UAL, JBHT, and more

April 17, 2024 | markets.businessinsider.com

Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views

April 17, 2024 | finance.yahoo.com

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 17, 2024 | fool.com

Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

April 17, 2024 | prnewswire.com

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

April 17, 2024 | msn.com

Vanda Pharmaceuticals (VNDA) Price Target Increased by 23.53% to 5.36

April 17, 2024 | msn.com

Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer

April 17, 2024 | markets.businessinsider.com

Vanda Pharma Rejects Future Pak's Takeover Proposals; Stock Climbs

April 17, 2024 | msn.com

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?

April 17, 2024 | finance.yahoo.com

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

April 17, 2024 | reuters.com

Vanda Pharmaceuticals rejects takeover proposal from Future Pak

April 17, 2024 | prnewswire.com

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

April 17, 2024 | investorplace.com

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?

April 16, 2024 | stocknews.com

3 Biotech Stocks to Watch for Lucrative Gains

April 14, 2024 | americanbankingnews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Lifted to "Buy" at StockNews.com

April 13, 2024 | americanbankingnews.com

Short Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Declines By 17.0%

April 3, 2024 | bizjournals.com

D.C. biotech scores FDA approval for key drug, stock surges

April 3, 2024 | investorplace.com

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 33% Today?

April 3, 2024 | msn.com

Biggest stock movers today: CALM, INTC, and more

April 3, 2024 | msn.com

Biotech Catches Major Premarket Bid Following FDA Approval

April 3, 2024 | benzinga.com

Why Is Vanda Pharmaceuticals Stock Trading Higher Today?

See More Headlines

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:VNDA
CUSIP: 92165910
CIK: 1347178
Web: www.vandapharma.com
Phone: (202) 734-3400
Fax: 202-296-1450
Employees: 203
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): $0.05
Trailing P/E Ratio: 104.82
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $2.51 million
Net Margins: 1.30%
Pretax Margin: 3.29%
Return on Equity: 0.46%
Return on Assets: 0.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.94
Quick Ratio: 4.92

Sales & Book Value

Annual Sales: $192.64 million
Price / Sales: 1.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.47 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 57,540,000
Free Float: 53,107,000
Market Cap: $301.51 million
Optionable: Optionable
Beta: 0.76

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Mihael H. Polymeropoulos M.D. (Age 64)
Founder, President, CEO & Chairman of The Board
Comp: $1.51M
Mr. Kevin Patrick Moran (Age 39)
Senior VP, CFO & Treasurer
Comp: $660.22k
Mr. Timothy Williams (Age 48)
Senior VP, General Counsel & Secretary
Comp: $724.38k
Mr. Joakim Wijkstrom (Age 58)
Senior VP & Chief Marketing Officer
Comp: $836.36k
Mr. Gunther Birznieks (Age 54)
Senior Vice President of Business Development
Comp: $690.83k
Mr. Scott L. Howell
Chief People Officer
Ms. Elizabeth Van Every
Head of Corporate Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed in 2024?: Vanda Pharmaceuticals' stock was trading at $4.22 at the start of the year. Since then, VNDA shares have increased by 24.2% and is now trading at $5.24.
View the best growth stocks for 2024 here.
Are investors shorting Vanda Pharmaceuticals?: Vanda Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decline of 17.0% from the March 15th total of 3,000,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 4.6% of the company's shares are sold short.
View Vanda Pharmaceuticals' Short Interest.
When is Vanda Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our VNDA earnings forecast.
How were Vanda Pharmaceuticals' earnings last quarter?: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings data on Wednesday, February, 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. The biopharmaceutical company had revenue of $45.27 million for the quarter, compared to analysts' expectations of $37 million. Vanda Pharmaceuticals had a net margin of 1.30% and a trailing twelve-month return on equity of 0.46%.
What ETFs hold Vanda Pharmaceuticals' stock?: ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and Horizon Kinetics Medical ETF (MEDX).iShares U.S. Pharmaceuticals ETF (IHE).

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?: 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Vanda Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).
Who are Vanda Pharmaceuticals' major shareholders?: Vanda Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.75%) and Profit Investment Management LLC (0.38%). Insiders that own company stock include Aranthan Jones II, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams.
View institutional ownership trends.
How do I buy shares of Vanda Pharmaceuticals?: Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VNDA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

VNDA Stock Price History

VNDA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

VNDA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™